Stereochemistry | ABSOLUTE |
Molecular Formula | C22H24ClFO7 |
Molecular Weight | 454.873 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@]34OC[C@@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)C=C1F
InChI
InChIKey=HYTPDMFFHVZBOR-VNXMGFANSA-N
InChI=1S/C22H24ClFO7/c1-2-29-17-6-3-12(8-16(17)24)7-13-9-14(4-5-15(13)23)22-20(28)18(26)19(27)21(10-25,31-22)11-30-22/h3-6,8-9,18-20,25-28H,2,7,10-11H2,1H3/t18-,19-,20+,21+,22+/m0/s1
Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.